🔔 Just Published in the journal of @ecancer The First data on the patterns of Esophageal cancer at the Garissa Cancer Center. ‼️ Late stage disease presentation ‼️ Mainly Ethnic Somalis 🚨Mainly Nomadic and rural communities Full link ⬇️ @garissahealth

🚨 ESMO 2025 | LBA15 (AIIMS Delhi) 🧬 Low-dose Pembrolizumab in TNBC Phase II RCT: Pembrolizumab 50 mg q6wk × 3 + NACT vs NACT alone 👉 pCR 53.8% vs 40.5% (Δ 13.3%, p = 0.047) ➡️ Nearly matches KN-522 results at a fraction of the dose and cost. 💊 Grade ≥ 3 AEs: 50% vs 59.5%

Information is key when you or your loved ones are diagnosed with cancer. You shouldn’t trust everything you read on the internet . Another new patient centers paper from our common sense oncology team @csoncol

#ESMO25 BEGONIA: Dato-DXd + Durvalumab as 1L in a/mTNBC 🔹 All-comer cohort: ORR 79%, mDoR 17.6 mo, mPFS 14 mo 🔹 PD-L1–high cohort: ORR 82% 💬 In line with ASCENT-03/04 and TROPION-Breast02, supporting chemo-free ADC+/-IO as a potential new 1L strategy in mTNBC

Thrilled to share our work from the common sense oncology consortium and my fellowship research project finally published in the European journal of cancer

Great faculty and session thanks @AORTIC_AFRICA and @QueensGlobalOnc for having us

My fellowship work just published in the Journal of European Cancer . Thanks @queensu and @csoncol . It’s been real

Bloomberg released an article highlighting efforts to reduce cancer drug doses while preserving outcomes & making treatments more affordable & accessible globally. Read it here: https://t.co/BxnkbuDdWW #CommonSenseOncology #CancerCare

🚨 Top Breast Cancer Data – #ESMO25 🚨 From early to metastatic settings, 13 key trials shaping practice: ✅ DESTINY-Breast11, Breast05, Breast09 ✅ monarchE, NATALEE, POSITIVE ✅ ASCENT-03, VIKTORIA-1, OptiTROP-Breast02, CULMINATE-2 & more @myESMO #esmo2025 @OncoAlert

#BRO25 Glad to announce our course is kicking off at 16:00 GMT+8 and will be live broadcast. Today we will have May Abdel-Wahab, Rolando Camacho, Michel Coleman, Ajrun Virasakdi, Felipe Rotiberg, & Qian Qin discussing global cancer control & international collaboration of #RT.

World Radiotherapy Awareness Day: One Voice for Radiotherapy, by @HamidMD10 https://t.co/nuHChZqe4Z

How do we know if a clinical trial truly matters to patients? Join us Next week on critical appraisal of clinical trials, their endpoints, and how these shape decision-making for patients, families https://t.co/3DbggiDZCg… @oncology_bg @CANCERKESHO @AORTIC_AFRICA

Thanks @oncodaily for the shout out. Here is a link to my substack cancer blogs :

Wrote a substack article on refugees and their neglected cancer care in east Africa . Please subscribe below and share https://t.co/w4yQ9S8PNI @UNmigration @IOMKenya @M_Waranle @WehliyeMohamed

Men’s health awareness month with a theme of men’s cancer care needs amid all the heavy lifting that society expects from men. Read my substack article and subscribe: https://t.co/70gk18Uh0w

Join us on 19tj june as we break down some of the top studies presented at @ASCO 2025. @CANCERKESHO @AORTIC_AFRICA

Happy Eidd to all brothers and sisters in Islam . I wrote about the parallel story of sacrifice of Eid-al Adha and cancer world. Subscribe to my Substack https://t.co/tTUtDezb4l

5/ ✅ We call for stronger adherence to #CSO principles across oncology trials. Let’s align cancer research with real-world value and patient-centered care. 📚 Full abstract: https://t.co/W94mzbKd37 @oncology_bg @fumikochino #GlobalOncology #ClinicalTrials #ASCO25

3/ Only 3 trials mentioned drug costs. These gaps show why we need trial designs that truly prioritize what matters to patients. CSO’s checklist offers a path to better: – Transparency – Practical endpoints – Affordability – Patient-reported outcomes #valuebasedcare

2/Title: Adherence of Published Randomized Phase 3 Cancer Trials to CSO Principles Key results – Only 50% of trials justified their control arms – Just 36% justified the primary endpoint – 14% included quality-of-life as an outcome – Only 2 trials addressed long-term toxicities

🧵1/ 🚨 Thrilled to announce the simultaneous publication of our fellowship project during #ASCO25 in #Chicago! We analyzed 50 phase 3 cancer trials published in top journals in 2023. 👇 What we found was eye-opening. #CommonSenseOncology